Acarix AB (OSTO:ACARIX) ROCE % : -219.65% (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Acarix AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Acarix AB's annualized ROCE % for the quarter that ended in Dec. 2023 was -219.65%.

Acarix AB ROCE % Historical Data

The historical data trend for Acarix AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acarix AB ROCE % Chart

Acarix AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-56.37

-52.01

-56.31

-100.68

-149.85

Acarix AB Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-139.42	-181.09	-148.10	-209.00	-219.65

Acarix AB ROCE % Calculation

Acarix AB's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-77.707	/	( ( (69.481 - 17.655)	+	(62.884 - 10.998) )	/ 2 )
	=	-77.707	/	( (51.826	+	51.886)	/ 2 )
	=	-77.707	/	51.856
	=	-149.85 %

Acarix AB's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-88.912	/	( ( (38.457 - 9.384)	+	(62.884 - 10.998) )	/ 2 )
	=	-88.912	/	( ( 29.073	+	51.886 )	/ 2 )
	=	-88.912	/	40.4795
	=	-219.65 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Acarix AB (OSTO:ACARIX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Acarix AB ROCE % Related Terms

Thank you for viewing the detailed overview of Acarix AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Acarix AB (OSTO:ACARIX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Acarix AB (OSTO:ACARIX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ACIXF:USA 7AC:Germany

Address

World Trade Center Malmo, Jungmansgatan 12, Malmo, SWE, 211 19

Website

https://www.acarix.com

Acarix AB is a Swedish medical technology company that develops innovative solutions for rapid AI-based exclusion of coronary artery disease (CAD). The CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. The CADScor System uses advanced acoustics and AI technology to non-invasively rule out CAD in less than 10 minutes, with at least 96% certainty.

Acarix AB (OSTO:ACARIX) Headlines

No Headlines